Silvant Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $178K | Hold |
1,411
| – | – | 0.01% | 210 |
|
|
2026
Q1 | $197K | Hold |
1,411
| – | – | 0.01% | 190 |
|
|
2025
Q4 | $173K | Hold |
1,411
| – | – | 0.01% | 194 |
|
|
2025
Q3 | $157K | Hold |
1,411
| – | – | 0.01% | 197 |
|
|
2025
Q2 | $156K | Hold |
1,411
| – | – | 0.01% | 192 |
|
|
2025
Q1 | $158K | Hold |
1,411
| – | – | 0.01% | 187 |
|
|
2024
Q4 | $130K | Hold |
1,411
| – | – | 0.01% | 207 |
|
|
2024
Q3 | $118K | Hold |
1,411
| – | – | 0.01% | 211 |
|
|
2024
Q2 | $96.8K | Hold |
1,411
| – | – | ﹤0.01% | 212 |
|
|
2024
Q1 | $103K | Hold |
1,411
| – | – | ﹤0.01% | 215 |
|
|
2023
Q4 | $114K | Hold |
1,411
| – | – | 0.01% | 203 |
|
|
2023
Q3 | $106K | Hold |
1,411
| – | – | 0.01% | 202 |
|
|
2023
Q2 | $109K | Hold |
1,411
| – | – | 0.01% | 202 |
|
|
2023
Q1 | $117K | Hold |
1,411
| – | – | 0.01% | 192 |
|
|
2022
Q4 | $121K | Hold |
1,411
| – | – | 0.01% | 191 |
|
|
2022
Q3 | $87K | Hold |
1,411
| – | – | 0.01% | 263 |
|
|
2022
Q2 | $87K | Hold |
1,411
| – | – | 0.02% | 222 |
|
|
2022
Q1 | $84K | Sell |
1,411
-24,463
| -95% | -$1.56M | 0.02% | 242 |
|
|
2021
Q4 | $1.88M | Sell |
25,874
-1,460
| -5% | -$101K | 0.32% | 70 |
|
|
2021
Q3 | $1.91M | Sell |
27,334
-2,472
| -8% | -$174K | 0.34% | 71 |
|
|
2021
Q2 | $2.05M | Sell |
29,806
-672
| -2% | -$44.9K | 0.32% | 75 |
|
|
2021
Q1 | $1.97M | Hold |
30,478
| – | – | 0.34% | 74 |
|
|
2020
Q4 | $1.78M | Sell |
30,478
-148
| -0.5% | -$8.93K | 0.3% | 79 |
|
|
2020
Q3 | $1.94M | Sell |
30,626
-536
| -2% | -$37.2K | 0.36% | 72 |
|
|
2020
Q2 | $2.4M | Hold |
31,162
| – | – | 0.43% | 61 |
|
|
2020
Q1 | $2.33M | Hold |
31,162
| – | – | 0.51% | 53 |
|
|
2019
Q4 | $2.02M | Sell |
31,162
-168
| -0.5% | -$10.9K | 0.37% | 76 |
|
|
2019
Q3 | $1.99M | Sell |
31,330
-289
| -0.9% | -$18.9K | 0.39% | 70 |
|
|
2019
Q2 | $2.14M | Sell |
31,619
-258
| -0.8% | -$17K | 0.38% | 74 |
|
|
2019
Q1 | $2.07M | Sell |
31,877
-180
| -0.6% | -$12K | 0.37% | 73 |
|
|
2018
Q4 | $2.01M | Sell |
32,057
-36,438
| -53% | -$2.55M | 0.4% | 79 |
|
|
2018
Q3 | $5.29M | Sell |
68,495
-466
| -0.7% | -$35.2K | 0.65% | 52 |
|
|
2018
Q2 | $4.88M | Buy |
68,961
+861
| +1% | +$60.8K | 0.6% | 62 |
|
|
2018
Q1 | $5.13M | Buy |
+68,100
| New | +$5.41M | 0.66% | 59 |
|
Other funds holding GILD
Silvant Capital Management's GILD Position: Q2 2026 in Review
Silvant Capital Management held its Gilead Sciences (GILD) position steady in Q2 2026 at 1,411 shares worth $178K. The position accounts for 0.01% of the portfolio, ranked #210.
Silvant Capital Management first reported a position in GILD in Q1 2018 and has held it in 34 quarters since. The position peaked at $5.29M in Q3 2018. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Silvant Capital Management held 1,411 shares of Gilead Sciences worth $178K as of Q2 2026.
- Silvant Capital Management left its Gilead Sciences share count unchanged in Q2 2026.
- Gilead Sciences made up 0.01% of Silvant Capital Management's portfolio in Q2 2026, its #210 holding.
- Silvant Capital Management first reported a position in Gilead Sciences in Q1 2018 and has held it in 34 quarters since.
- Silvant Capital Management's Gilead Sciences position peaked at $5.29M in Q3 2018.
- 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.